Fighting for patients' access to new treatments and cures. Chief Public Affairs Officer & Head of Strategic Initiatives at @PhRMA.
Washington, DC
Joined March 2009
- Tweets2.6K
- Following3.5K
- Followers2.8K
- Likes99
Pinned Tweet
As football season begins, fans will see hospital names on stadiums across the country. What's much harder to see is how profits generated through the 340B program are being used.
Learn more: ow.ly/Z1bm50ZLuNQ
The Treasury Department recently announced their COINs regulation proposal which was expanded to include the biopharmaceutical industry.
We are committed to working with the administration to protect national security, preserve patient access and strengthen American leadership in medicine development.
These overly broad restrictions risk blocking companies from promising science, giving China more control over how new medicines are developed and who gets access. Isolating America from new medical advancements undermines our national security goals and could prevent U.S. patients from getting breakthrough medicines.
Policymakers should target real security risks while strengthening America’s ability to compete. The goal should be simple: keep the United States the best place in the world to discover, develop and manufacture new medicines.
Generic medicines are meant to support increased competition and reduce costs for patients. But did you know that since 2014, PBMs have excluded 900% more generics from the lists they develop to determine which medicines will be covered by commercial insurers?
If policymakers don’t act, PBMs – not patents – will keep standing between patients and the lower-cost medicines that our IP system has incentivized and delivered.
Learn more: ow.ly/oRMX50ZZSOu
During Intellectual Property Month, we must acknowledge the power of America’s IP system.
Our IP system ensures American patients have access to more treatment options than anywhere else in the world, with the average prescription for generic medicines costing just under $7.
ow.ly/lnHk50ZXPst
Big hospital systems, clinics and their for-profit partners captured $142B in profits from 340B medicine markups in 2025 alone. If we see continued 20% annual growth, that could exceed $1T in cumulative profits from 340B markups over the next five years.
Low-income patients shouldn’t pay more than hospitals for 340B medicines. Congress must fix 340B.
ow.ly/T9kB50ZTs5r
I sat down with @BrodyMullinsDC on @the535news to talk about why the fight for PBM reform isn't over. Congress has taken important steps towards fixing PBMs, but too many patients are still paying full price at the pharmacy counter while their insurance company gets a steep discount. These are the barriers people tell us they want fixed and we must keep working to fix them: ow.ly/QiWZ50ZTfgv
Looking forward to working with Eric Cantor and leveraging his decades-long experience in policymaking to make America the best place to research and develop new treatments and cures.
We are excited to announce Eric Cantor as our next president and CEO.
Eric is well respected among policy leaders in Washington and around the world, with a long track record of working effectively across the political spectrum in support of biomedical research and patients’ access to medicines. He joins PhRMA at a pivotal moment for America’s biopharmaceutical industry.
Read more: phrma.org/resources/phrma-se…
Consider what it takes to bring a new medicine to patients:
10 to 15 years of R&D.
$2.6 billion on average.
Only about 1 in 10 candidates entering clinical trials ultimately receives FDA approval.
And innovation doesn’t stop there. Research continues to find new ways to help more patients.
Learn more: ow.ly/7buL50ZSLmx
A new analysis of 75 large 340B hospitals found 83% of some of the largest 340B hospitals analyzed did not include information about prescription drug assistance in their financial assistance policy.
That should raise a basic question: If hospitals and clinics are buying medicines at steep discounts, are low income and uninsured patients seeing the benefit?
It’s time to fix 340B and ensure the program directly benefits the patients it is supposed to serve.
Learn more: ow.ly/ABAV50ZShXQ
Great few days in London joining Bank of America and McDermott Will & Schulte for conversations about the future of biopharma. From China and AI to global competition for R&D and manufacturing, one thing is clear: U.S. leadership in medical innovation isn’t guaranteed.
We should meet that competition by making America the best place in the world to research, develop and manufacture the next generation of medicines.
PBMs are increasingly positioning themselves as champions of affordability. But for many patients, the experience and hard data tell a different story. Three PBMs control 80% of the prescription drug market and have significant influence over which medicines patients can access, what they'll pay and the hurdles they may face accessing their doctor-prescribed treatments.
Patients deserve results, not a new narrative. Learn more: ow.ly/XHT050ZPMha
50 cents of every dollar spent on medicines goes to middlemen. That’s why the work on #PBM reform isn’t finished.
Enjoyed talking with @BrodyMullinsDC from @the535news about what patients are still facing — and how sustained public affairs campaigns can help put overlooked issues on the policy agenda.
Watch my conversation: ow.ly/xyox50ZP9Km
PDUFA is critical to patients and Congress most move swiftly to reauthorize it. Without it, we put America’s biopharmaceutical leadership at risk, and American patients will pay the price.
Learn more: ow.ly/13cI50ZNZqC
PBMs are working hard to convince patients and policymakers that they’re lowering health care costs. But changing the talking points doesn’t change the facts: PBMs negotiate billions in rebates and discounts, with no guarantee that patients see those savings at the pharmacy counter. Patients deserve more transparency and accountability from the middlemen controlling access to medicines. Learn more at PhRMA.org/PBMs.
Pennsylvania shows what smart policy can do. Its leaders made the state attractive for biopharmaceutical investment, and the state has reaped the rewards in jobs and growth. America should take note. Read more about last week’s @axios event: ow.ly/Z94Y50ZNyNt
Keeping the U.S. at the forefront of developing new medicines starts with supporting the research, talent and investment happening in states like Pennsylvania.
Tune into @axios Live for a closer look at what it will take to keep that momentum going>>>
Pennsylvania is a biopharmaceutical hub, home to an ecosystem of world-class research institutions, a strong workforce pipeline and investment in advanced manufacturing.
Watch LIVE ▶️ @Axios Beyond the Breakthrough: Pennsylvania’s Innovation Edge!
xitter.cf/i/broadcasts/1PKqrNzkb…
Since 2017, the FDA has approved a growing number of cell and gene therapies that target the root causes of serious diseases and can offer long-term, potentially curative results. Our health care system must evolve as these advances continue.
Learn more: ow.ly/YgYb50ZJxTe
One key topic from @steveubl's conversation with @BrodyMullinsDC and @camoosomiller on @decidersshow: Where biopharmaceutical research happens matters.
China is investing heavily in research and clinical trial infrastructure. As Steve points out, the U.S. needs policies that make it easier to develop the next generation of medicines here.
Expanding biopharmaceutical manufacturing in the U.S. also requires investing in the workforce behind it.
Upskilling, reskilling and talent development will be critical to creating high-quality jobs and supporting long-term manufacturing growth.
ow.ly/hekW50ZGG0w
